At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Optimizing Smoking Cessation Interventions for People Living With HIV in Nairobi, Kenya
In Brief
A Phase 3 clinical trial evaluating Bupropion, Positively smoke free, and 1 other intervention for HIV and Smoking Cessation. Completed, enrolled 300 participants across 1 site.
Detailed Summary
The proposed study will use a factorial design to evaluate the most promising and accessible behavioral and pharmacologic treatments aimed at achieving maximal efficacy for smoking cessation among people living with HIV who smoke. The study will randomize 300 participants people living with HIV , who smoke and who are receiving care in HIV clinics affiliated with the Center for International Health, Education, and Biosecurity in Nairobi, Kenya to one of the following 4 conditions: (1) bupropion + Positively Smoke Free (an 8 session tailored behavioral intervention for people living with HIV smokers); (2) bupropion + Standard of Care (brief advice to quit); (3) Placebo + Positively Smoke Free; and (4) Placebo + Standard of Care.
Study Details
Timeline
Interventions
medication for smoking cessation
an 8 session, tailored behavioral intervention for treating tobacco dependence
Standardized brief advice to quit smoking (standard of care)